Comparison · NCT03230838-2e8b78f1
Ceftolozane/Tazobactam vs Meropenem: Number of Participants With ≥1 Adverse Events (AEs)
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Ceftolozane/Tazobactam vs Meropenem: Number of Participants With ≥1 Adverse Events (AEs). Trial comparisons, record NCT03230838-2e8b78f1. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03230838-2e8b78f1
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.59 | 0.492 | 0.681 | wilson | |
| Risk in group 2 | 0.606 | 0.437 | 0.753 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0161 | -0.193 | 0.176 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.973 | 0.707 | 1.34 | log | |
| Odds ratio, group 1 over group 2 | 0.935 | 0.419 | 2.09 | log | |
| Number needed to treat, for one fewer participant with the outcome on Ceftolozane/Tazobactam than on Meropenem | 62.3 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Ceftolozane/Tazobactam | Ceftolozane 20 mg/kg and tazobactam 10 mg/kg (maximum 1 g and 0.5 g/dose) administered intravenously (IV) every 8 hours for 7-14 days | 59 | 100 | OG000 |
| Group 2 | Meropenem | Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for 7-14 days | 20 | 33 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Number of Participants With ≥1 Adverse Events (AEs)
- Description
An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a medicinal product or protocol specified procedure, whether or not considered related to the medicinal product or protocol specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.
- Time frame
- Up to Day 88
- Population
- All randomized participants who received any amount of study treatment.
Source ClinicalTrials.gov
Trial
- Title
- MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)
- NCT number
- NCT03230838
- Phases
- PHASE2
- Conditions
- Complicated Urinary Tract Infection, Pyelonephritis
- Interventions
- Ceftolozane/Tazobactam, Meropenem
- Lead sponsor
- Merck Sharp & Dohme LLC
- Results first posted
- 2021-12-01
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03230838?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03230838-2e8b78f1